» Articles » PMID: 17919129

The Neurobiology of Autism

Overview
Journal Brain Pathol
Date 2007 Oct 9
PMID 17919129
Citations 172
Authors
Affiliations
Soon will be listed here.
Abstract

Improving clinical tests are allowing us to more precisely classify autism spectrum disorders and diagnose them at earlier ages. This raises the possibility of earlier and potentially more effective therapeutic interventions. To fully capitalize on this opportunity, however, will require better understanding of the neurobiological changes underlying this devastating group of developmental disorders. It is becoming clear that the normal trajectory of neurodevelopment is altered in autism, with aberrations in brain growth, neuronal patterning and cortical connectivity. Changes to the structure and function of synapses and dendrites have also been strongly implicated in the pathology of autism by morphological, genetic and animal modeling studies. Finally, environmental factors are likely to interact with the underlying genetic profile, and foster the clinical heterogeneity seen in autism spectrum disorders. In this review we attempt to link the molecular pathways altered in autism to the neurodevelopmental and clinical changes that characterize the disease. We focus on signaling molecules such as neurotrophin, Reelin, PTEN and hepatocyte growth factor, neurotransmitters such as serotonin and glutamate, and synaptic proteins such as neurexin, SHANK and neuroligin. We also discuss evidence implicating oxidative stress, neuroglial activation and neuroimmunity in autism.

Citing Articles

Exploring EEG resting state differences in autism: sparse findings from a large cohort.

Dede A, Xiao W, Vaci N, Cohen M, Milne E Mol Autism. 2025; 16(1):13.

PMID: 39994801 PMC: 11853566. DOI: 10.1186/s13229-025-00647-3.


Vitamin C and Gallic Acid Ameliorate Motor Dysfunction, Cognitive Deficits, and Brain Oxidative Stress in a Valproic Acid-Induced Model of Autism.

Tarahomi P, Arab M, Seyedinia S, Rahmani M, Rashidy-Pour A, Vafaei A Brain Behav. 2025; 15(2):e70262.

PMID: 39910830 PMC: 11799046. DOI: 10.1002/brb3.70262.


Unraveling the Endocannabinoid System: Exploring Its Therapeutic Potential in Autism Spectrum Disorder.

Jana A, Nath A, Sen P, Kundu S, Alghamdi B, Abujamel T Neuromolecular Med. 2024; 26(1):20.

PMID: 38744725 PMC: 11093854. DOI: 10.1007/s12017-024-08781-6.


Amygdalar neurotransmission alterations in the BTBR mice model of idiopathic autism.

Bove M, Palmieri M, Santoro M, Agosti L, Gaetani S, Romano A Transl Psychiatry. 2024; 14(1):193.

PMID: 38632257 PMC: 11024334. DOI: 10.1038/s41398-024-02905-z.


Porphyrinuria in Autism Spectrum Disorder: A Review.

Bjorklund G, Semenova Y, El-Ansary A, Al-Ayadhi L Curr Med Chem. 2023; 31(42):6911-6925.

PMID: 38031776 DOI: 10.2174/0109298673259183231117073347.


References
1.
Ylisaukko-Oja T, Rehnstrom K, Auranen M, Vanhala R, Alen R, Kempas E . Analysis of four neuroligin genes as candidates for autism. Eur J Hum Genet. 2005; 13(12):1285-92. DOI: 10.1038/sj.ejhg.5201474. View

2.
Buchsbaum M, Hollander E, Haznedar M, Tang C, Wei T, Solimando A . Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol. 2001; 4(2):119-25. DOI: 10.1017/S1461145701002280. View

3.
Branchi I, Francia N, Alleva E . Epigenetic control of neurobehavioural plasticity: the role of neurotrophins. Behav Pharmacol. 2004; 15(5-6):353-62. DOI: 10.1097/00008877-200409000-00006. View

4.
Coutinho A, Sousa I, Martins M, Correia C, Morgadinho T, Bento C . Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels. Hum Genet. 2007; 121(2):243-56. DOI: 10.1007/s00439-006-0301-3. View

5.
Zimmerman A, Connors S, Matteson K, Lee L, Singer H, Castaneda J . Maternal antibrain antibodies in autism. Brain Behav Immun. 2006; 21(3):351-7. DOI: 10.1016/j.bbi.2006.08.005. View